Báez-Saldaña Armida, Zendejas-Ruiz Iván, Revilla-Monsalve Cristina, Islas-Andrade Sergio, Cárdenas Araceli, Rojas-Ochoa Alberto, Vilches Alonso, Fernandez-Mejia Cristina
Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Am J Clin Nutr. 2004 Feb;79(2):238-43. doi: 10.1093/ajcn/79.2.238.
Several studies have shown that biotin affects glucose homeostasis. Serum biotin concentrations are lower in subjects with type 2 diabetes than in control subjects. Lymphocyte propionyl-CoA carboxylase (PCC; EC 6.4.1.3) activity has proved to be a sensitive indicator of biotin status that is more accurate than is serum biotin concentration.
We studied the activity of PCC, pyruvate carboxylase (PC; EC 6.4.1.1), and acetyl-CoA carboxylase (ACC; EC 6.4.1.2) in type 2 diabetic and nondiabetic subjects. The effect of biotin administration (6.14 micro mol/d) on the activity of these enzymes and on several plasma metabolites was also studied.
We compared the activities of carboxylases in circulating lymphocytes from patients with type 2 diabetes (n = 24) with those in circulating lymphocytes from nondiabetic subjects (n = 30). We also assessed the effect of biotin administration for 14 and 28 d on the activity of these enzymes and on the concentrations of several metabolites (type 2 diabetic patients, n = 10; nondiabetic subjects, n = 7).
No significant differences in lymphocyte carboxylase activities were found between the type 2 diabetic patients and the nondiabetic subjects. Biotin administration increased the activity of PCC, PC, and ACC in all the subjects. No significant change in glucose, insulin, triacylglycerol, cholesterol, or lactate concentration was observed with the treatment in either the diabetic or the nondiabetic subjects.
The activity of carboxylases does not differ significantly between type 2 diabetic and nondiabetic subjects. Pharmacologic doses of biotin increase lymphocyte PCC, PC, and ACC activities.
多项研究表明,生物素会影响葡萄糖稳态。2型糖尿病患者的血清生物素浓度低于对照组。淋巴细胞丙酰辅酶A羧化酶(PCC;EC 6.4.1.3)活性已被证明是生物素状态的敏感指标,比血清生物素浓度更准确。
我们研究了2型糖尿病患者和非糖尿病患者中PCC、丙酮酸羧化酶(PC;EC 6.4.1.1)和乙酰辅酶A羧化酶(ACC;EC 6.4.1.2)的活性。还研究了给予生物素(6.14微摩尔/天)对这些酶活性和几种血浆代谢物的影响。
我们比较了2型糖尿病患者(n = 24)循环淋巴细胞中的羧化酶活性与非糖尿病患者(n = 30)循环淋巴细胞中的羧化酶活性。我们还评估了给予生物素14天和28天对这些酶活性和几种代谢物浓度的影响(2型糖尿病患者,n = 10;非糖尿病患者,n = 7)。
2型糖尿病患者和非糖尿病患者之间淋巴细胞羧化酶活性无显著差异。给予生物素可增加所有受试者中PCC、PC和ACC的活性。糖尿病患者和非糖尿病患者在接受治疗后,血糖、胰岛素、三酰甘油、胆固醇或乳酸浓度均未观察到显著变化。
2型糖尿病患者和非糖尿病患者之间羧化酶活性无显著差异。药理剂量的生物素可增加淋巴细胞PCC、PC和ACC的活性。